Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

November - December 2010

 

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of the hepatitis c virus, in healthy subjects. Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bólyai J, Mayers D. Antimicrob Agents Chemother. 2010 Nov 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21060109

 

Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Conjeevaram HS, Wahed AS, Afdhal N, et al. Gastroenterology. 2010 Nov 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21070775

 

Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Iacobellis A, Perri F, Valvano MR, Caruso N, Niro GA, Andriulli A. Clin Gastroenterol Hepatol. 2010 Nov 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21092761

 

Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. Muir AJ, Hu KQ, Gordon SC, et al. J Viral Hepat. 2010 Nov 25. doi: 10.1111/j.1365-2893.2010.01402.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21108699

 

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Lam KD, Trinh HN, Do ST, et al. Hepatology. 2010 Nov;52(5):1573-80.

http://www.ncbi.nlm.nih.gov/pubmed/21038410

 

Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Pham ST, Bull RA, Bennett JM, et al. Hepatology. 2010 Nov;52(5):1564-72.

http://www.ncbi.nlm.nih.gov/pubmed/21038409

 

Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Lindenburg CE, Lambers FA, Urbanus AT, et al. Eur J Gastroenterol Hepatol. 2010 Oct 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21042221

 

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Buti M, Lurie Y, Zakharova NG, et al. Hepatology. 2010 Oct;52(4):1201-7.

http://www.ncbi.nlm.nih.gov/pubmed/20683847

 

Systemic vasculitis in patients with hepatitis C virus infection with and without detectable mixed cryoglobulinemia. Terrier B, Sčne D, Dechartres A, et al. J Rheumatol. 2010 Oct 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20952479

 

Sporadic reappearance of minute amounts of HCV RNA after successful therapy stimu-lates cellular immune responses. Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Gastroenterology. 2010 Oct 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21040725

 

Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. Wang CC, Cook L, Tapia KA, et al. J Clin Virol. 2010 Oct 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20951635

 

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial. Gane EJ, Roberts SK, Stedman CA, et al. Lancet. 2010 Oct 30;376(9751):1467-75. Epub 2010 Oct 14.

http://www.ncbi.nlm.nih.gov/pubmed/20951424

 

The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents chronic hepatitis C. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. . Gastroenterology. 2010 Oct 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21036173

 

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or 2b to patients with chronic hepatitis C. Marcellin P, Forns X, Goeser T, et al. Gastro-enterology. 2010 Oct 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21034744

 

Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis c: a 12-week, randomized, double-blind, placebo-controlled trial.

Diez-Quevedo C, Masnou H, Planas R, et al. J Clin Psychiatry. 2010 Oct 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21034680

 

A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.

Neri S, Bertino G, Petralia A, et al. J Clin Gastroenterol. 2010 Oct;44(9):e210-7.

http://www.ncbi.nlm.nih.gov/pubmed/20838237

 

Basic and Applied Science, Pre-Clinical Studies

 

Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. J Infect Dis. 2010 Oct 1;202(7):984-90.

http://www.ncbi.nlm.nih.gov/pubmed/20726768

 

 

Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-α and ribavirin combination therapy in patients with chronic hepatitis C virus infection. Tatsumi T, Takehara T, Miyagi T, et al. Hepatol Res. 2010 Oct 7. doi: 10.1111/j.1872-034X.2010.00734.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21040277

 

Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24h. Devitt E, Lawless MW, Sadlier D, A Browne J, Walsh C, Crowe J. Eur J Gastroenterol Hepatol. 2010 Oct;22(10):1211-20.

http://www.ncbi.nlm.nih.gov/pubmed/20631625

 

Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Hepatology. 2010 Nov;52(5):1581-9.

http://www.ncbi.nlm.nih.gov/pubmed/20812318

 

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin a induced cis-trans isomerisation in domain II of NS5A. Coelmont L, Hanoulle X, Chatterji U, et al. PLoS One. 2010 Oct 27;5(10):e13687.

http://www.ncbi.nlm.nih.gov/pubmed/21060866

 

CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice. Aoyama T, Inokuchi S, Brenner DA, Seki E. Hepatology. 2010 Oct;52(4):1390-400.

http://www.ncbi.nlm.nih.gov/pubmed/20683935

 

Conformational anti-cytochrome P4502E1 (CYP2E1) auto-antibodies contribute to necro-inflammatory injury in chronic hepatitis C. Sutti S, Vidali M, Mombello C, Sartori M, Albano E. J Viral Hepat. 2010 Oct;17(10):685-90. doi: 10.1111/j.1365-2893.2010.01359.x.

http://www.ncbi.nlm.nih.gov/pubmed/20738774

 

A new natural α-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV. Yan R, Zhao Z, He Y, et al. Peptides. 2010 Oct 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20950663

 

Dynamic coinfection with multiple viral subtypes in acute hepatitis C. Smith JA, Aberle JH, Fleming VM, et al.

http://www.ncbi.nlm.nih.gov/pubmed/21067369

 

HIV/HCV Coinfection

 

Modeling the probability of sustained virological response to Therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Medrano J, Neukam K, Rallón N, et al. Clin Infect Dis. 2010 Nov 15;51(10):1209-16.

http://www.ncbi.nlm.nih.gov/pubmed/20964522

 

 

 

 

Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. Rizza SA, Cummins NW, Rider DN, Saeed S, Klein MB, Badley AD. AIDS. 2010 Nov 13;24(17):2639-44.

http://www.ncbi.nlm.nih.gov/pubmed/20802294

 

Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients. Li Vecchi V, Soresi M, Colomba C, et al. World J Gastroenterol. 2010 Nov 7;16(41): 5225-32.

http://www.ncbi.nlm.nih.gov/pubmed/21049556

 

The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010. Loko MA, Salmon D, Carrieri P, et al. BMC Infect Dis. 2010 Oct 22;10(1):303. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20969743

 

Immunological status does not influence hepatitis C virus or liver fibrosis in HIV-Hepatitis C virus-coinfected patients. Collazos J, Cartón JA, Asensi V. AIDS Res Hum Retroviruses. 2010 Oct 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20977357

 

Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. Bhattacharya D, Umbleja T, Carrat F, et al. J Acquir Immune Defic Syndr. 2010 Oct 1;55(2):170-5.

http://www.ncbi.nlm.nih.gov/pubmed/20622678

 

Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes. Collazos J, Cartón J, Asensi V. HIV Med. 2010 Oct 14. doi: 10.1111/j.1468-1293.2010.00886.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20946441

 

Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. Morello J, Cuenca L, Soriano V, et al. J Infect Dis. 2010 Oct 15;202(8):1185-91.

http://www.ncbi.nlm.nih.gov/pubmed/20812847

 

Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. Pineda JA, González J, Ortega E, et al. J Viral Hepat. 2010 Oct;17(10):714-9. doi: 10.1111/j.1365-2893.2009.01229.x.

http://www.ncbi.nlm.nih.gov/pubmed/20002560

 

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Pineda JA, Caruz A, Rivero A, et al. Clin Infect Dis. 2010 Oct 1;51(7):788-95.

http://www.ncbi.nlm.nih.gov/pubmed/20804372

 

 

Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). Sherman KE, Andersen JW, Butt AA, et al. J Acquir Immune Defic Syndr. 2010 Oct 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20921898

 

An artificial neural network improves the non-invasive diagnosis of significant fibrosis in HIV/HCV coinfected patients. Resino S, Seoane JA, Bellón JM, et al. J Infect. 2010 Nov 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21073895

 

Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: The HEPAIG study. Piroth L, Larsen C, Binquet C, et al. Hepatology. 2010 Dec;52(6):1915-21. doi: 10.1002/hep.23959. Epub 2010 Nov 9.

http://www.ncbi.nlm.nih.gov/pubmed/21064156

 

Complementary and Alternative Medicine

 

S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. Filipowicz M, Bernsmeier C, Terracciano L, Duong FH, Heim MH. PLoS One. 2010 Nov 8;5(11):e15492.

http://www.ncbi.nlm.nih.gov/pubmed/21079746

 

Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Freedman ND, Curto TM, Morishima C, et al. Aliment Pharmacol Ther. 2010 Nov 2. doi: 10.1111/j.1365-2036.2010.04503.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21083592

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Humanistic and economic impacts of hepatitis C infection in the United States. Dibona-ventura MD, Wagner JS, Yuan Y, L'italien G, Langley P, Ray Kim W. J Med Econ. 2010 Nov 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21091098

 

Formal patient education improves patient knowledge of hepatitis c in vulnerable popu-lations. Surjadi M, Torruellas C, Ayala C, Yee HF Jr, Khalili M. Dig Dis Sci. 2010 Oct 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20972850

 

Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Petta S, Amato M, Cabibi D, et al. Hepatology. 2010 Nov;52(5):1543-52.

http://www.ncbi.nlm.nih.gov/pubmed/20799355

 

Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. Murakami Y, Tanaka M, Toyoda H, et al. BMC Med Genomics. 2010 Oct 22;3:48.

http://www.ncbi.nlm.nih.gov/pubmed/20969775

 

Importance of Patient, Provider, and Facility Predictors of Hepatitis C Virus Treatment in Veterans: A National Study. Kramer JR, Kanwal F, Richardson P, et al. Am J Gastroenterol. 2010 Nov 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21063393

 

Syringe exchange programs --- United States, 2008. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010 Nov 19;59(45):1488-91.

http://www.ncbi.nlm.nih.gov/pubmed/21085091

 

Evaluation of acute hepatitis C infection surveillance --- United States, 2008. MMWR Morb Mortal Wkly Rep. 2010 Nov 5;59(43):1407-10. Centers for Disease Control and Prevention (CDC).

http://www.ncbi.nlm.nih.gov/pubmed/21048562

 

Fatigue and depressive symptoms associated with chronic viral hepatitis patients. health-related quality of life (HRQOL). Karaivazoglou K, Iconomou G, Triantos C, et al. Ann Hepatol. 2010 Oct 1;9(4):419-27.

http://www.ncbi.nlm.nih.gov/pubmed/21057161

 

Transfusion-transmissible viral infections among US military recipients of whole blood and platelets during Operation Enduring Freedom and Operation Iraqi Freedom. Hakre S, Peel SA, O'Connell RJ, et al. Transfusion. 2010 Oct 7. doi: 10.1111/j.1537-2995.2010.02906.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20946199

 

Patients' perceptions of information and support received from the nurse specialist during HCV treatment. Grogan A, Timmins F. J Clin Nurs. 2010 Oct;19(19-20):2869-78. doi: 10.1111/j.1365-2702.2010.03239.x.

http://www.ncbi.nlm.nih.gov/pubmed/20846231

 

Guidance for clinical trials for children and adolescents with chronic hepatitis C. Wirth S, Kelly D, Sokal E, et al. J Pediatr Gastroenterol Nutr. 2010 Nov 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21076340

 

Liver Cancer

 

Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Am J Surg Pathol. 2010 Nov;34(11):1630-6.

http://www.ncbi.nlm.nih.gov/pubmed/20975341

 

Synergistic Effect of Celecoxib on 5-fluorouracil-induced Apoptosis in Hepatocellular Carcinoma Patients. Bassiouny AR, Zaky A, Neenaa HM. Ann Hepatol. 2010 Oct 1;9(4):410-8.

http://www.ncbi.nlm.nih.gov/pubmed/21057160

 

Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: A population-based cohort study (JPHC Study). Ishiguro S, Inoue M, Tanaka Y, et al.  Cancer Lett. 2010 Oct 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21035947

 

Increased risk for malignant neoplasms among patients with cirrhosis. Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Björnsson E. Clin Gastroenterol Hepatol. 2010 Oct 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21029788

 

Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Yorita K, Takahashi N, Takai H, et al. Liver Int. 2010 Oct 21. doi: 10.1111/j.1478-3231.2010.02359.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20964802

 

Factors associated with use of ultrasonography screening for hepatocellular carcinoma among hepatitis B or C carriers. Cho ER, Shin A, Choi KS, Lee HY, Kim J. Cancer Epidemiol. 2010 Oct 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20947465

 

Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular Carcinoma Huh-7 cells. Liao PC, Ng LT, Lin LT, Richardson CD, Wang GH, Lin CC. J Med Food. 2010 Oct 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20946021

 

Comparative Analysis of outcome in patients with hepatocellular carcinoma exceeding the Milan criteria treated with liver transplantation versus partial hepatectomy. Canter RJ, Patel SA, Kennedy T, et al. Am J Clin Oncol. 2010 Oct 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20938319

 

Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans. Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. J Immigr Minor Health. 2010 Oct 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20890660

 

Meta-analysis: interferon improves outcomes following ablation or resection of hepato-cellular carcinoma. Singal AK, Freeman DH Jr, Anand BS. Aliment Pharmacol Ther. 2010 Oct;32(7):851-8. doi: 10.1111/j.1365-2036.2010.04414.x.

USA. aksingal@utmb.edu

http://www.ncbi.nlm.nih.gov/pubmed/20659285

 

Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Nakamoto Y, Mizukoshi E, Kitahara M, et al. Clin Exp Immunol. 2010 Nov 19. doi: 10.1111/j.1365-2249.2010.04246.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21087443

 

Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: A meta-analysis of randomized controlled trials. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Int J Cancer. 2010 Nov 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21077159

 

Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? Lok AS. J Gastroenterol Hepatol. 2010 Nov 11. doi: 10.1111/j.1440-1746.2010.06576.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21070361